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Summary
 
Platelet-activating factor (PAF) is a potent phospholipid mediator with diverse biological activ-
ities in addition to its well-known ability to stimulate platelet aggregation. Pharmacologic stud-
ies had suggested a role for PAF in pregnancy, neuronal cell migration, anaphylaxis, and endo-
toxic shock. Here we show that disruption of the PAF receptor gene in mice caused a marked
reduction in systemic anaphylactic symptoms. Unexpectedly, however, the PAF receptor–defi-
cient mice developed normally, were fertile, and remained sensitive to bacterial endotoxin.
These mutant mice clearly show that PAF plays a dominant role in eliciting anaphylaxis, but
that it is not essential for reproduction, brain development, or endotoxic shock.
Key words: platelet-activating factor • platelet-activating factor receptor • anaphylaxis • 
endotoxic shock • gene targeting
 
P
 
latelet-activating factor (PAF
 
1
 
; 1-
 
O
 
-alkyl-2-acetyl-
 
sn
 
-glycero-3-phosphocholine) is a potent phospholipid
mediator with various biological activities, including plate-
let activation, airway constriction, hypotension, and vascu-
lar permeation (1–4). PAF acts by binding to a G protein–
coupled seven transmembrane receptor (5). Through G
proteins, PAFR links to signal transduction mechanisms,
including turnover of phosphatidylinositol, elevation in in-
tracellular calcium concentration (6), and activation of many
kinases, e.g., phosphatidylinositol-3 kinase (7), protein ki-
nase C (8), and mitogen-activated protein kinase (9). We
and others have cloned PAFR cDNAs of guinea pig (10),
human (11–14), and rat (15) and a PAFR gene of mouse
(16). A unique PAFR has been identified in each species by
the molecular cloning technique, although possible exis-
tence of PAFR subtypes has been suggested by biochemical
or pharmacologic methods (17, 18).
PAF is synthesized not only in various blood cells but
also in many other tissues, e.g., early mammalian embryo
(19), fetal lung (20), kidney (21), and brain (22) under
physiological conditions. Thus, PAF, even at low concen-
trations, has been considered to constitutively regulate var-
ious physiological processes such as reproduction (19, 23),
blood pressure (24), neural development (25), and hippo-
campal long-term potentiation (18). Despite extensive
studies, the physiological importance of PAF in vivo re-
mains largely unknown.
In addition to its role as a physiological mediator, PAF
has been believed to be associated with the pathology of
anaphylaxis and endotoxic shock. Systemic anaphylaxis is a
rapid, often fatal type-I allergic reaction characterized by
acute airway constriction, heart rate (HR) alteration, hy-
potension, and vascular leakage (26, 27); many anaphylactic
symptoms can be mimicked by PAF injection in animals (4,
5). Indeed, PAF is released rapidly from antigen-stimulated
mast cells (28) and basophils (29) in vitro. In studies in
vivo, an increase in blood PAF level is also detected after
antigen challenge to sensitized animals (30). PAFR antago-
nists, which inhibit the binding of PAF to the receptor, ex-
ert protective effects on anaphylaxis in animal models (30–32).
 
1
 
Abbreviations used in this paper: 
 
ANOVA, analysis of variance
 
; 
 
ES, embry-
onic stem; HR, heart rate; LTB
 
4
 
, leukotriene B
 
4
 
; MAP, mean arterial
pressure; NO, nitric oxide; PAF, platelet-activating factor; R
 
L
 
, total lung
resistance.
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However, the precise role of PAF among a lot of allergic
mediators in the development of anaphylactic responses is
unclear.
Endotoxic or septic shock is the result of activation of
the immune system by endotoxin/LPS, a component of
Gram-negative bacterial cell wall. In this state, macrophages
produce large amounts of cytokines such as TNF-
 
a
 
 and IL-6,
as well as other inflammatory mediators, including PAF,
that are released into the circulation (33, 34). Thus, these
events lead to hypotension, tissue injury, vascular leakage,
and frequently, death. As is the case in anaphylaxis, PAF
per se is capable of eliciting many symptoms associated
with endotoxic shock (4, 5). Further, it has been reported
that the blood PAF level increased during endotoxemia
(30, 35) and the PAF acetylhydrolase activity decreased in
plasma of patients with sepsis (36). The administration of
PAFR antagonists to animals and humans protects them from
the deleterious effects of endotoxin (30, 32, 37–40). Our
recent demonstration that transgenic mice overexpressing
PAFR are hypersensitive to endotoxin has suggested that
PAF plays an exaggerating role in the in vivo response to
endotoxin (41).
To date, our ability to address the pathophysiological
role of PAF has largely depended on the use of structurally
diverse PAFR antagonists. However, pharmacologic stud-
ies often encounter problems related to the specificity of
drugs. Indeed, several PAFR antagonists are demonstrated
to have an inhibitory effect on the activity of intracellular
PAF acetylhydrolase, an inactivating enzyme of PAF (42,
43). Some other antagonists inhibit histamine effects
through the interaction with its G protein–coupled recep-
tor (40, 44).
To clearly identify both the nonredundant physiological
role of PAF and the pathophysiological role of PAF with-
out the use of possibly nonspecific PAFR antagonists, we
generated animals in which the PAFR signaling was con-
genitally declined by targeted disruption of the PAFR gene
in murine embryonic stem (ES) cells. We report here that
the resulting PAFR-deficient mice were fertile and devel-
oped normally. Furthermore, although these mice showed
the markedly attenuated anaphylactic symptoms, the re-
sponses to endotoxin remained intact. Thus, our studies
demonstrate that PAF plays a dominant role in eliciting
anaphylaxis, and is not essential for reproduction, brain de-
velopment, or endotoxic shock.
 
Materials and Methods
 
Reagents.
 
Materials and chemicals were obtained from the
following sources. 
 
a
 
-[
 
32
 
P]dCTP (111 TBq/mmol) and transfer
membrane (Hybond-N
 
1
 
) were from Amersham (Tokyo, Japan);
restriction enzymes and DNA-modifying enzymes were from
Takara (Kyoto, Japan) or Toyobo (Kyoto, Japan); agaroses (Sea
Kem and Nu Sieve) were from FMC (Rockland, ME); PAF (1-
 
O
 
-hexadecyl-2-acetyl-
 
sn
 
-glycero-3-phosphocholine) and leuko-
triene B
 
4
 
 (LTB
 
4
 
) were from Cayman Chemical (Ann Arbor, MI);
[
 
3
 
H]WEB 2086 (499.5 GBq/mmol) and [
 
3
 
H]acetyl-PAF (370
GBq/mmol) were from Du Pont/New England Nuclear (Tokyo,
Japan); fatty acid–free BSA, grade VI OVA, and endotoxin (LPS;
 
Escherichia coli
 
 serotype O127:B8, code No. L-3129) were from
Sigma Chemical Co. (St. Louis, MO); lyso-PAF was from Cascade
Biochem (Berkshire, UK); pyrogen-free saline was from Otsuka
Pharmaceuticals (Tokyo, Japan); RPMI 1640 medium was from
Nissui (Tokyo, Japan). Other materials and reagents were of ana-
lytical grade. PAF and LTB
 
4
 
 were dissolved in pyrogen-free saline
containing 0.25% BSA just before use. Endotoxin was suspended
in saline. Unlabeled WEB 2086 was a gift from Boehringer Ingel-
heim (Ingelheim, Germany) and was dissolved in saline by soni-
cation at a concentration of 0.5 mg/ml.
 
Targeted Disruption of Mouse PAFR Gene.
 
The murine PAFR
genomic DNA was isolated by screening a 
 
l
 
FixII 129/Sv ge-
nomic library (Stratagene, La Jolla, CA) (16) with guinea pig
PAFR cDNA (10). The targeting vector was constructed in
pBluescript vector (Stratagene) using a 10.7-kb EcoRI fragment
of the genomic DNA, a PGK-neo cassette, and an MC1-tk cas-
sette (Fig. 1 
 
a
 
). The PGK-neo cassette was inserted into the PstI
site in the exon. E14-1 cells were electroporated with NotI-lin-
earized targeting vector and selected with G418 (225 
 
m
 
g active
weight/ml) and fluoroiodoadenosyluracine (FIAU; 0.2 
 
m
 
M). The
ES clones carrying the PAFR-targeted mutation on one allele
through the homologous recombination event were screened by
Southern blot analysis after ScaI digestion with a 5
 
9
 
 flanking 0.6-
kb SalI–EcoRI fragment (5
 
9
 
 probe shown in Fig. 1 
 
a
 
). This frag-
ment is located at the margin of the murine PAFR genomic
DNA clone used; the SalI site derives from the polycloning sites
of 
 
l
 
FixII vector. The 5
 
9
 
 probe identified a 9.1-kb mutant band in
addition to a 11.1-kb wild-type band (data not shown). Results
were verified by hybridization of BamHI restriction digests with a
3
 
9
 
 flanking 1.4-kb EcoRI–EcoRI fragment (3
 
9
 
 probe shown in
Fig. 1 
 
a
 
). Hybridization of ScaI restriction digests either with a
1.2-kb Eco47III–SpeI fragment containing the entire exon
(PAFR probe shown in Fig. 1 
 
a
 
) or with a 1.1-kb AatI–BglII
fragment of a neomycin resistance gene (Neo probe shown in
Fig. 1 
 
a
 
) was also performed to ensure a single integration site.
The former probe identified 9.1- and 3.5-kb mutant bands in ad-
dition to a 11.1-kb wild-type band (see Fig. 1 
 
b
 
), and the latter
probe identified a 9.1-kb mutant band (data not shown).
Mutant clones were injected into blastocysts of C57BL/6 mice
and the resulting male chimeras were mated to C57BL/6 females
to test for germline transmission of the mutation. Offspring de-
rived from ES cells were identified by coat color and screened for
the presence of the targeted allele by Southern blot analysis of
ScaI-digested tail DNA using 5
 
9
 
 probe (Fig. 1 
 
b
 
). For the follow-
ing experiments, homozygous mutants and wild-type littermates
were obtained by intercrossing heterozygous mutant mice under
specific pathogen-free conditions. The genotypes of mice were
determined by Southern blot analysis of ScaI-digested tail DNA
using the PAFR probe (Fig. 1 
 
b
 
).
 
Northern Hybridization.
 
Total RNA was prepared from 2%
casein-induced neutrophils as previously described (16). The
RNA (1 
 
m
 
g) was electrophoresed, transferred to a nylon mem-
brane, and hybridized (16) with either the PAFR probe shown in
Fig. 1 
 
a
 
 or a human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA probe (Clontech, Palo Alto, CA).
 
Radioligand Binding Assay.
 
Lung membranes were prepared
and used for ligand binding assay as described (41). Peritoneal ex-
udate macrophages were obtained using thioglycollate as de-
scribed in reference 16. The cells were cultured in 6-well dishes
at 10
 
6
 
 cells/well. After incubation for 2 h, nonadherent cells were
washed away with RPMI 1640 medium containing 10% heat-
inactivated FCS (GIBCO BRL, Rockville, MD). Adherent mac- 
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rophages were then cultured for 1 or 2 d. Binding of [
 
3
 
H]WEB
2086 (20 nM) or [
 
3
 
H]acetyl-PAF (10 nM) was competed with
unlabeled WEB 2086 (20 
 
m
 
M) in Hepes-Tyrode’s buffer (pH
7.4) containing 0.1% BSA (Hepes-BSA buffer) at 20
 
8
 
C for 90
min or 25
 
8
 
C for 60 min, respectively. The cells were washed
three times with cold Hepes-BSA buffer and lysed with 5% Tri-
ton X-100. The radioactivity associated with the cells was mea-
sured by liquid scintillation counting.
 
Measurement of Intracellular Calcium Concentration.
 
Neutrophils
were loaded with 3 
 
m
 
M Fura-2AM (Dojindo, Kumamoto, Japan)
at 37
 
°
 
C for 1 h and resuspended in calcium-free Hepes-Tyrode’s
buffer (pH 7.4) at 2 
 
3 
 
10
 
6
 
 cells/ml. Intracellular calcium concen-
trations were measured using a fluorometer (CAF-110; JASCO,
Tokyo, Japan) as described previously (45).
 
Sensitization of Mice. pafr
 
1/1
 
 and 
 
pafr
 
2/2
 
 (18–22-wk-old) male
mice were given an intraperitoneal injection of OVA (100 
 
m
 
g),
aluminum hydroxide gel (1 mg), and pertussis toxin (300 ng;
Kaken Pharmaceutical, Tokyo, Japan) (26). Elicitation of anaphy-
laxis or bleeding were performed 18–21 d after the immuniza-
tion. Serum levels of OVA-specific IgE and IgG1 were deter-
mined by ELISA as described in the PharMingen (San Diego,
CA) protocol. In brief, 96-well flat-bottomed plates (Corning
Glass Works, Corning, NY) were coated with either rat anti–
mouse IgE antibody (clone R35-72) or OVA. Bound IgE or
IgG1 was detected with biotinylated OVA in combination with
horseradish peroxidase–conjugated streptavidin or horseradish
peroxidase–conjugated anti–mouse IgG1 (clone G1-6.5), respec-
tively. 2,2
 
9
 
-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma
Chemical Co.) was used as a substrate to generate the color reac-
tion, which was read at 405 nm. The Ig levels of the samples
were estimated using serum of an OVA-immunized mouse as a
standard, and were compared using the Mann-Whitney U test.
 
Measurement of Mean Arterial Pressure and HR.
 
Under urethane
anesthesia (1.5 g/kg, intraperitoneal), mice were cannulated with
PE-10 polyethylene tubing (Clay Adams, Parsippany, NJ) into
the right femoral artery. The tubing was filled with heparinized
saline and connected to a pressure transducer (TP-200T; Nihon
Kohden, Tokyo, Japan). The blood pressure signals were ampli-
fied (AP-600G; Nihon Kohden) and stored into a tape recorder.
HR was computed using a tachometer (AT-601G; Nihon Koh-
den) on the basis of an electrocardiogram. The data were fed into
a computer (PC9801RX; NEC, Tokyo, Japan) to calculate the
mean values. Body temperature was maintained at 37 
 
6
 
 1
 
8
 
C with
a heating pad by monitoring rectal temperature. The cannulated
mice were injected with 200 
 
m
 
g/kg of PAF (10 ml/kg), 200 
 
m
 
g/kg
of lyso-PAF (10 ml/kg), 15 mg/kg of endotoxin (1 ml/kg), or
150 
 
m
 
g of OVA (100 
 
m
 
l/head) via the right femoral vein.
 
Bronchopulmonary Responses.
 
Total lung resistance (R
 
L
 
) was
measured as previously described (41, 46, 47). Mechanically ven-
tilated mice were challenged with 500 
 
m
 
g OVA via the jugular
vein in a 100-
 
m
 
l bolus. The lungs were removed intact 5 min af-
ter the challenge of OVA. For histological analysis, the lungs
were frozen in liquid nitrogen, fixed in Carnoy’s solution, and
stained with hematoxylin and eosin (46). In other experiments,
the dissected lungs were weighed and placed in a gravity convec-
tion oven at 90
 
8
 
C for 72 h to determine dry weights for calcula-
tion of wet weight/dry weight ratios (46).
 
Determination of Cytokine Levels.
 
Adherent peritoneal macro-
phages were prepared as described in reference 16 and were cul-
tured on 48-well dishes at 2.5 
 
3 
 
10
 
5
 
 cells/well in 250 
 
m
 
l of RPMI
1640 medium supplemented with 10% heat-inactivated FCS
(Moregate, Melbourne, Australia). The cells were exposed to en-
dotoxin (100 ng/ml) plus mouse rIFN-
 
g
 
 (100 U/ml; Genzyme,
Cambridge, MA) for 24 h. The supernatants were harvested and
stored at 
 
2
 
80
 
8
 
C. Concentrations of TNF-
 
a
 
 and IL-6 were deter-
mined in duplicate using murine ELISA kits obtained from Gen-
zyme and Amersham, respectively. Limits of detection for TNF-
 
a
 
and IL-6 were 35 and 40 pg/ml, respectively. Data shown are av-
erages from two separate experiments. Unstimulated macrophages
released undetectable levels of the cytokines.
 
Results and Discussion
 
Generation of PAFR-deficient Mice.
 
A gene-targeting con-
struct  was generated in which an open reading frame of the
G protein–coupled PAFR gene was inserted by a PGK-
neo cassette (Fig. 1 
 
a
 
). The construct was electroporated into
E14-1 ES cells. Two targeted ES clones were identified af-
ter screening 670 ES clones resistant to both G418 and fluo-
roiodoadenosyluracine by Southern blot analysis of ScaI-
digested genomic DNA using the 5
 
9
 
 probe shown in Fig. 1 
 
a
 
(data not shown). Further Southern blot analyses with the 3
 
9
 
probe after BamHI digestion, and Neo probe and PAFR
probe after ScaI digestion, demonstrated the absence of re-
arrangements or extra insertional events in these two clones
(data not shown). The targeted clones were injected into
C57BL/6 blastocysts, and the resulting male chimeras bred
to C57BL/6 females to produce mice heterozygous for the
disrupted PAFR allele. Crossings between F1 or F2 het-
erozygous mice under specific pathogen-free conditions
yielded 82 wild-type (
 
pafr
 
1/1
 
), 140 heterozygous (
 
pafr
 
1/2
 
)
mutant, and 72 homozygous (
 
pafr
 
2/2
 
) mutant mice, consis-
tent with a normal 1:2:1 Mendelian distribution of off-
spring (
 
x2 test). pafr2/2 mouse lines were established from
both clones.
Inactivation of the PAFR gene was confirmed by ge-
nomic Southern analysis (Fig. 1 b) and by Northern analysis
of RNA isolated from neutrophils (Fig. 1 c). Neither peri-
toneal macrophages nor lung tissues from pafr2/2 mice dis-
played any detectable binding sites for the PAFR antagonist
WEB 2086 (16, 48; data not shown), confirming the loss of
surface receptors. In pafr2/2 mice, challenge with PAF no
longer induced an increase in intracellular calcium concen-
tration in neutrophils (49) (Fig. 1 d) or a decrease in mean
arterial pressure (MAP; reference 50; Fig. 1 e). These results
provide compelling evidence that the PAFR plays an es-
sential role in PAF-induced calcium mobilization in neu-
trophils and in systemic hypotension.
Development, Reproduction, and Cardiac Homeostasis. pafr2/2
mice were healthy in appearance and grew normally up to
1 yr of age. There were no changes in blood cell popula-
tions, differential leukocyte counts, or serum biochemical
parameters (data not shown). Light microscopic examina-
tion of major organs (brain, heart, lung, liver, kidney, pitu-
itary, thyroid, adrenal, thymus, spleen, gastrointestinal tract,
bone, bone marrow, and skin) revealed no differences in
morphology between pafr1/1 and pafr2/2 mice at 13–16 wk
old (data not shown). A requirement for PAF in neural cell
migration had previously been proposed based on the find-
ing that mutation in the LIS1 gene encoding a subunit of
brain PAF acetylhydrolase causes Miller-Dieker lissenceph-1782 A Dominant Role for Platelet-activating Factor in Anaphylactic Responses
aly (25). The apparent lack of brain malformation in pafr2/2
mice suggests, however, that the LIS1 subunit may have
other function(s) relevant to brain development that are
unrelated to PAF. This is consistent with a recent report
that LIS1 reduces microtubule catastrophe events by inter-
acting with tubulin (51).
PAF has also been proposed to play significant roles in
reproductive functions such as implantation and parturition1783 Ishii et al.
in various species (52–54). In fact, human preembryos pro-
duced by in vitro fertilization show an increased rate of im-
plantation after exposure to PAF (53) and transgenic mice
that overproduce PAFR display reproductive disorders
(41). Hence, there existed a possibility that pafr2/2 mice
might be infertile. Contrary to this expectation, however,
the homozygous pafr2/2 mice were fertile and produced
healthy litters of normal size (6.2 6 1.2 [pafr2/2 3 pafr2/2;
n 5 5] versus 8.0 6 0.7 [pafr1/2 3 pafr1/2; n 5 7]; mean
litter size 6 SEM, P ø 0.2, the unpaired t test [two-
tailed]). These results suggest that PAF is not essential for
normal development and reproduction of mice, although
we cannot rule out the possible existence of additional
PAFR subtypes as previously suggested by biochemical and
pharmacologic experiments (17, 18). Furthermore, it is also
possible that there may be receptor-independent actions
of PAF.
MAP was measured through a catheter placed in the
femoral artery. There were no significant differences in the
baseline of both parameters between pafr1/1 and pafr2/2
mice (101 6 5 versus 107 6 4 mmHg; mean 6 SEM, n 5
5 each, P ø 0.4, the unpaired t test [two-tailed]). Although
intravenously administered PAF has a potent hypotensive
effect, as shown in Fig. 1 e, the lack of difference in MAP
between pafr1/1 and pafr2/2 mice suggests that PAF may
not be a mediator involved in setting the basal tone of vas-
cular smooth muscle. HR of pafr1/1 and pafr2/2 mice were
also indistinguishable (586 6 22 versus 560 6 28 beats/
min; mean 6 SEM, n 5 5 each, P ø 0.5, the unpaired t
test [two-tailed]). However, on the contrary, we observed
in OVA-sensitized mice (see below) that HR of pafr2/2
mice (648 6 7 beats/min; mean 6 SEM, n 5 10) was sig-
nificantly higher than that of pafr1/1 mice (570 6 18 beats/
min; n 5 12, P 5 0.003, the Mann-Whitney U test),
whereas MAPs were comparable between pafr1/1 and pafr2/2
mice. Sensitization for active anaphylaxis may be associated
with many changes, e.g., in levels of antigen-specific Igs of
different isotypes, numbers of various effector cells, and lo-
cal concentrations of immunomodulatory cytokines. It is
possible that some of these changes cause the observed in-
crease in the basal HR.
Active Systemic Anaphylaxis. To directly evaluate the
pathophysiological role of PAF in systemic anaphylaxis,
pafr1/1 and pafr2/2 mice were sensitized with OVA in the
presence of adjuvants (26). This treatment caused mice of
both genotypes to develop comparable and significant lev-
els of OVA-specific IgE and IgG1 (data not shown), which
mediate systemic anaphylaxis (27). The sensitized animals
were injected intravenously with OVA to elicit systemic
anaphylaxis. Cardiovascular or bronchopulmonary parame-
ters were measured to assess the severity of the shock. Soon
after challenge with OVA, all pafr1/1 mice developed se-
vere and irreversible hypotension (Fig. 2 a). In this shock
state, HR response to OVA was biphasic. OVA caused a
rapid onset of tachycardia that reached a maximal increase
of z20% after 10 min, followed by bradycardia (Fig. 2 b).
The tachycardia may be a compensatory response due to
baroreceptor reflex. Five of six pafr1/1 mice died within 25
min (Fig. 2), and the remaining mouse died after 48 min.
In contrast, the fall in MAP was much milder in pafr2/2
mice compared with pafr1/1 mice (Fig. 2 a). Furthermore,
HR remained stable upon the administration of OVA (Fig.
2 b). Only one of seven pafr2/2 mice died after 36 min. Le-
thality among pafr2/2 mice monitored 50 min after the an-
Figure 1. Disruption of the PAFR gene in
mice. (a) Gene-targeting strategy: structure and
partial restriction maps of the PAFR gene, tar-
geting construct, and predicted targeted allele,
and location of the probes used for hybridiza-
tion analyses. Solid boxes, exon containing the
entire PAFR open reading frame (PAFR ORF);
hatched boxes, PGK promoter (PGK-neo) and
neomycin-resistance gene with poly(A) signal;
gray boxes, MC1 promoter (MC1-tk) and herpes
simplex virus thymidine kinase gene. The direc-
tion of transcription for each gene is indicated
by an arrow. Restriction endonuclease sites: E,
EcoRI; H, HindIII; Ba, BamHI; P, PstI; and Sc,
ScaI. (b) Southern blot analysis of tail DNA from
pafr1/1 (1/1), pafr1/2 (1/2), and pafr2/2 (2/2)
mice. The wild-type (11.1-kb) and targeted
(9.1- and 3.5-kb) ScaI fragments are detected
using the PAFR probe shown in a. (c) Northern
blot analysis of PAFR mRNA expression in
pafr1/1 (1/1), pafr1/2 (1/2), and pafr2/2 (2/2)
neutrophils. PAFR mRNA (upper blot) is identi-
fied using the PAFR probe indicated in a. The
expression of GAPDH mRNA is also shown
(lower blot). (d) Intracellular calcium measure-
ments in C57BL/6 (WT) and pafr2/2 ( 2/2)
neutrophils. Changes in intracellular calcium in response to 10 nM PAF or 10 nM LTB4 were determined using Fura-2AM. Agonists were added at the
times indicated by the arrows. (e) MAP measurements of pafr1/1 (1/1) and pafr2/2 (2/2) mice. PAF (200 mg/kg) was administered intravenously at the
times indicated by the arrows. Lyso-PAF (200 mg/kg) had no effects on MAP values in either group (data not shown). Nearly identical data were ob-
tained with two animals in each group.1784 A Dominant Role for Platelet-activating Factor in Anaphylactic Responses
tigen challenge was significantly lower than that of pafr1/1
mice (P ,0.005, as determined by Fisher’s exact test).
Next, RL was measured in tracheostomized, mechani-
cally ventilated mice. All pafr1/1 mice showed a rapid in-
crease in RL after the intravenous injection of OVA (Fig. 3 a).
In comparison to the response in pafr1/1 mice, antigen
challenge of pafr2/2 mice produced a significantly smaller
increase in RL (Fig. 3 a). Lung tissues in pafr1/1 mice given
OVA were characterized by airway constriction associated
with folding of airway epithelium, alveolar wall thickening,
alveolar distortion, and edema (Fig. 3 b). Pulmonary edema
due to increased vascular permeability was further assessed
by measuring wet weight/dry weight ratios (Fig. 3 c). In
marked contrast to pafr1/1 mice, pafr2/2 mice displayed no
response to the antigen challenge, either in the wet
weight/dry weight ratios (Fig. 3 c) or in lung histology
(Fig. 3 b).
These results clearly demonstrate a dominant role for
PAF in the anaphylactic responses. Because pafr2/2 mice
still show milder symptoms of anaphylaxis, chemical medi-
ators other than PAF, such as eicosanoids (55), histamine,
or serotonin, probably also contribute to the anaphylactic
responses, albeit to a much lesser extent.
The results of this study elucidated a large contribution
of PAF to allergen-induced airway obstruction. As for the
effects of PAF on the bronchopulmonary system, we re-
ported that PAFR overexpressing mice show a remarkable
airway hypersensitivity to methacholine (41). Thus, PAF is
likely to play an important role in the pathophysiology of
the bronchopulmonary system. However, the murine air-
ways are somehow unresponsive to the intravenously ad-
ministered PAF (41, 50, 56), whereas PAF given in the
same manner elicited severe hypotension in mice (Fig. 1 e;
reference 50). This is in contrast to our present data from
immunologically stimulated mice which shows that PAF is
deeply involved in both hypotension and bronchoconstric-
tion. The murine airways, therefore, do not appear to re-
spond to the blood-released PAF, which exerts deleterious
effects on the cardiovascular system. Only PAF produced
in the lung may act on the airways in a paracrine fashion.
Endotoxic Shock. To assess the importance of PAF and
PAFR in the development of endotoxic shock, PAFR-
deficient mice were examined for their sensitivity to endo-
toxin using three kinds of assays. First, pafr1/1 and pafr2/2
mice were treated with endotoxin given intravenously at a
dose range of 7.5–30 mg/kg. As shown in Table 1, there
was no significant difference in lethality in this model be-
tween pafr1/1 and pafr2/2 mice. At each dose, mice of both
genotypes exhibited apparently equivalent symptoms of en-
dotoxic shock: lethargy, piloerection, and diarrhea. We
next measured MAP of anesthetized mice in endotoxemia
for 100 min as shown in Fig. 2 a. pafr2/2 mice showed hy-
potensive responses to endotoxin that were indistinguish-
able from those of pafr1/1 mice (Fig. 4). The drop in MAP
during endotoxic shock was slow but progressive, in con-
trast to the rapid drop observed during anaphylactic shock
(Fig. 2 a). Finally, the ability of pafr2/2 macrophages to re-
spond to endotoxin was evaluated. Thioglycollate-stimu-
lated peritoneal macrophages were exposed to endotoxin
to induce expression of TNF-a and IL-6. Levels of these
cytokines in the culture medium were measured by ELISA.
In  pafr1/1 and pafr2/2 macrophages, endotoxin induced
Figure 2. Cardiovascular responses during anaphylaxis. Data points show the mean MAP (a) and the mean HR (b) of pafr1/1 (open symbols) and pafr2/2
(closed symbols) male mice for the 5-min period preceding each time point. Results are expressed as percentage of baseline 6 SEM. The baseline corre-
sponded to the mean value over a 10-min period before intravenous injection of OVA (squares) or saline (circles) at time 0. Numbers in parentheses are the
numbers of animals alive at the indicated times. MAP and HR of dead mice were taken to be zero. The basal MAP of pafr1/1 and pafr2/2 mice were 89 6 4 and
93 6 3 mmHg, and the basal HR were 570 6 18 and 648 6 7 beats/min (mean 6 SEM; n 5 10 and 12, respectively). *P ,0.005, #P ,0.05 versus
both the pafr2/2 OVA group and the pafr1/1 saline group, ‡P ,0.005, †P ,0.05 versus the pafr2/2 saline group, as determined by analysis of variance
(ANOVA) with Scheffe’s test for pair-wise comparisons. OVA had no effects on MAP or HR in unsensitized mice (data not shown).1785 Ishii et al.
equivalent levels of TNF-a (10,250 and 10,544 pg/ml, re-
spectively) and IL-6 (4,352 and 4,314 pg/ml, respectively).
During endotoxic shock, a strong hypotensive factor, ni-
tric oxide (NO), is synthesized. A PAFR antagonist is re-
ported to inhibit the endotoxin-stimulated NO production
in cultured murine macrophages (57), suggesting that en-
dotoxin-induced hypotension is mediated by PAF and NO
in this order. However, our results demonstrate that endo-
toxic shock can be elicited without the action of PAF.
Contrary to our expectation based on the previous phar-
macologic reports, PAFR-deficient mice failed to acquire
resistance to endotoxin. The intact susceptibility to endo-
toxin is consistent with our present data that macrophages
from PAFR-deficient mice produced TNF-a and IL-6, the
inflammatory cytokines induced by endotoxin, to the same
extent as those from wild-type mice. Since we have previ-
ously reported an increased susceptibility to endotoxin in
PAFR overexpressing mice (41), it is very intriguing that
Figure 3. Bronchopulmonary responses during anaphylaxis. (a) Comparison of change in RL between pafr1/1 (open symbols) and pafr2/2 (closed symbols)
mice. Data from male mice are expressed as mean percentage of baseline 6 SEM. The baseline RL corresponded to the mean values over a 5-min period
before the intravenous injection of OVA. (squares; n 5 8 each) or saline (circles; n 5 3 each) at time 0. The baselines of pafr1/1 and pafr2/2 mice were 0.41 6
0.02 and 0.41 6 0.01 cmH2O/ml/s (mean 6 SEM; n 5 11), respectively. No mice died during the recordings. *P , 0.05 versus the pafr2/2 OVA group,
†P ,0.05 versus the pafr1/1 saline group, ‡P ,0.03 versus both the pafr2/2 OVA group and the pafr1/1 saline group, as determined by ANOVA with
Scheffe’s test for pair-wise comparisons. No statistically significant response was detected in the OVA-challenged pafr2/2 mice compared with the saline-
challenged mice. (b) Histology of the fixed lung tissue from a pafr1/1 (top) and a pafr2/2 (bottom) mouse. Hematoxylin and eosin staining. Scale bar: 100
mm. (c) Determination of wet weight/dry weight ratios of the lungs of pafr1/1 (1/1) and pafr2/2 (2/2) mice given OVA (hatched bars; n 5 6 each) or saline
(open bars; n 5 3 each). Data are presented as the mean 6 SEM. *P 5 0.0001 versus the pafr2/2 OVA group, as determined by ANOVA with Scheffe’s
test for pair-wise comparisons.1786 A Dominant Role for Platelet-activating Factor in Anaphylactic Responses
PAFR-deficient mice show normal sensitivity to endo-
toxin. It may be that PAF functions in vivo not as an essen-
tial, but as an exaggerating factor for endotoxic shock.
There are noteworthy pharmacologic reports exhibiting
that ID50 values of various PAF antagonists for death due to
anaphylaxis are nearly equal to those for PAF-induced
death (32), whereas the doses of PAFR antagonists for in-
hibiting endotoxin-induced death are usually .10 times
higher than those for inhibiting PAF-induced death (39).
These data may suggest that PAFR antagonists attenuate
the symptoms of anaphylaxis and endotoxic shock in differ-
ent ways. The latter might be PAFR independent.
Concluding Remarks. Although PAF has pleiotropic bi-
ological activities in vitro, the effects of deleting the PAFR
gene were restricted to anaphylactic responses, i.e., PAFR-
deficient mice were fertile and grew normally and were as
sensitive to endotoxin as the wild-type mice. Thus, we
conclude that although PAF is a dominant anaphylactic medi-
ator, it may not be required for reproduction, neural devel-
opment, or endotoxic shock. PAFR antagonists should, there-
fore, be useful in preventing anaphylactic responses in humans
without causing serious mechanism-based side effects. Recent
mouse models demonstrated that neither IgE (26) nor its
high-affinity receptor, FceRI (27), is required for active
systemic anaphylaxis, further supporting the validity of PAF
as a target mediator for preventing and treating the disorder.
Table 1. Lethal Toxicity of Bacterial Endotoxin
Dose of endotoxin
Lethality (deaths/total)
pafr1/1 pafr2/2
mg/kg
7.5 0/3 0/3
15.0 3/8 3/8
22.5 5/8 4/8
30.0 7/8 7/8
Sex- and age-matched pafr2/2 and pafr1/1 mice (unanesthetized, 14–27
wk old) were injected with endotoxin in a volume of 10 ml/kg via tail
vein. Survival was monitored for 3 d. There were no deaths after 3 d.
No statistical significance was observed at any doses in pafr2/2 mice
compared with pafr1/1 mice (Fisher’s exact test).
Figure 4. Change in MAP during endotoxemia. pafr1/1 and pafr2/2
mice are represented by the open and closed squares, respectively. Data
from female mice are shown as in Fig. 2 a. The baselines of pafr1/1 and
pafr2/2 mice were 101 6 5 and 107 6 4 mmHg (mean 6 SEM; n 5 5
each). No mice died during the recordings.
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